Advocacy through groups like BCAN and the AUA shapes urologic oncology policy—driving funding, screening access, and equity in cancer care, the authors write.
Feature|Articles|October 1, 2025
Top 5 urologic oncology headlines you missed in September 2025
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
We recap notable headlines from last month in the urologic oncology space.
Advertisement
Advertisement
September 2025 welcomed several notable stories in urologic oncology, highlighting the continued advances across the field as well as the persistent areas of unmet needs. In this monthly recap, Urology Times® rounds up the most important regulatory decisions, clinical trial milestones, and practice-changing developments from September 2025.
Related to this article
The PDUFA target action date is in the fourth quarter of 2026.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
Better detection has changed prostate cancer care. Patients choosing radical treatment still need better protection from the disease returning.
Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and PCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.
Sandip Prasad, MD, MPhil, discusses the evolving role of chemoablation in recurrent low-grade, intermediate-risk NMIBC, including patient selection and treatment considerations.
Eugene Cone, MD, discusses recombinant BCG for NMIBC, including ongoing clinical evaluation and its potential to address ongoing BCG supply challenges.
A national study found that use of MRI before prostate biopsy increased in US hospitals from 2017 through the first half of 2026.
Advertisement
Advertisement